CN110996933A - 用于帕金森病的预防性和/或支持性治疗处理的药剂 - Google Patents
用于帕金森病的预防性和/或支持性治疗处理的药剂 Download PDFInfo
- Publication number
- CN110996933A CN110996933A CN201880042374.6A CN201880042374A CN110996933A CN 110996933 A CN110996933 A CN 110996933A CN 201880042374 A CN201880042374 A CN 201880042374A CN 110996933 A CN110996933 A CN 110996933A
- Authority
- CN
- China
- Prior art keywords
- propionic
- disease
- salts
- parkinson
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 230000003319 supportive effect Effects 0.000 title claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 9
- 230000003449 preventive effect Effects 0.000 title abstract description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 41
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 13
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 8
- 235000019260 propionic acid Nutrition 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- -1 alkali metal salt Chemical class 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000015219 food category Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/05—Propionic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及用于帕金森病的预防性和/或支持治疗处理的药剂，所述药剂包含生理有效量的丙酸和/或丁酸和/或其生理上相容的盐或酯。
Description
本发明涉及用于帕金森病的预防性和/或支持性治疗处理的药剂。
许多疾病与肠道定殖不足有关，也就是说，无论是由于定殖不足或由于维持身体机能的必需成分的丧失，肠道的微生物组失衡。对于诸如肥胖症、溃疡性结肠炎、多发性硬化(MS)、帕金森病、可能还有精神病、以及风湿性疾病形式和牛皮癣等所有这些疾病，都可以检测到肠道微生物组的显著变化。这表明由于共同原因或由于交互作用的影响因素，微生物组和各自的疾病是相互关联的。
进一步发现，肠道微生物组可受到所消耗的营养类型的影响，并且能够适应给定食品种类要满足的要求。这意味着，可以通过采取旨在改善患者免疫状况的适当饮食措施来改变不利于患者免疫状况的不利肠微生物群。
本发明基于以下发现：与健康对照个体相比，在帕金森病中微生物组发生了特征性变化。特别是，微生物组中几乎不存在或根本不存在产生短链脂肪酸的细菌。因此，在健康对照者的肠道中作为降解产物存在的短链脂肪酸缺乏。Braak推测帕金森病始于肠道。这与微生物组从患有帕金森病的小鼠向健康小鼠的转移产生可比较的帕金森病图像这一观察结果一致。
帕金森病患者缺乏产生短链脂肪酸的微生物，导致缺乏特别是乙酸、丙酸和丁酸。虽然食物会大量供应乙酸，但通常不会弥补丙酸和丁酸的不足。
α-突触核蛋白是存在于大脑中并在帕金森病中发挥作用的转运蛋白，其可以在疾病非常早期在肠道内检测到，并可以作为疾病的指示剂。这也表明疾病与肠道中发生的事情之间存在联系。
已经进行了通过采取医学或饮食措施来补偿肠道定殖不足的实验，但这仅在有限的程度上取得了成功。
已经令人惊讶地发现，丙酸和丁酸对帕金森病的发展和进程具有积极作用。这也适用于其生理上可耐受的盐和酯。还观察到这些物质的靶向给药改善了帕金森病的药物治疗，即具有增强效果。特别是，可以显著降低通常用于治疗帕金森病的多巴胺能药物的剂量。
因此，本发明涉及用于帕金森病的预防性和/或支持性治疗处理的药剂，所述药剂包含生理有效量的丙酸和/或丁酸和/或其生理上可接受的盐或酯。
本发明提出的药剂可以出于预防性和治疗性目的而向易患帕金森病的人或向帕金森病患者给药。但是，该药剂特别适合于另外接受常规药物治疗的帕金森病患者的支持性治疗处理。
本发明的药剂可以单独含有丙酸或丁酸，或含有其组合。但是,以生理上可接受的盐的形式给药是优选的，其中生理上重要的金属盐是最重要的。除了碱金属盐和碱土金属盐以外，这些盐还可以包括锌盐和铁盐。
特别优选的是丙酸和丁酸的钠盐、钾盐、镁盐和钙盐。
另外，丙酸和丁酸也可以以酯的形式给药。C1至C6醇的酯，特别是甲酯和乙酯特别合适。酯在体内水解成游离酸。
本发明的药剂可以以常规形式给药，例如片剂、糖衣丸(dragées)、丸剂、胶囊、锭剂、粉剂和颗粒剂。以果汁、滴剂和茶形式的液体形式给药也是可行的。在任何情况下，该药剂旨在口服给药。
优选的药剂递送形式是片剂、胶囊和粉剂。含有单位剂量的本发明药剂的片剂和胶囊优选每天给药两次。例如可以将粉剂搅拌成饮料/饮品，或添加到食物中。
前述药剂递送形式的单位剂量为0.2-5g，特别是0.3-3g。片剂、胶囊和粉剂的特别优选量是0.5-2.0g，旨在各自用于早晨和晚上给药，并且若合适，另外在中午给药，特别是与膳食一起。
特别优选的是丙酸和丁酸或其盐和酯以单剂联合给药，但也可以以分开的形式联合给药。例如，对于上述总剂量，在这种情况下的重量比可以为3:1至1:3，特别是3:2至2:3。
如已经提到的，本发明提出的药剂可以用于帕金森病患者的支持性治疗处理。在这种情况下，除常规药物治疗外，还与例如左旋多巴和其他常用的多巴胺能药物一起给药。本发明药剂的剂量如上所述。
在患者研究中，对丁酸/丁酸盐的作用进行了研究，其中超过1,000名测试患者各自至少参与了一年。与早上、中午和晚上的膳食一起，每日三个剂量，施用总计6g丁酸或丁酸盐(作为盐)和医师指导的药物(左旋多巴等)。确定了全身状况的显著改善，尤其是在运动机能方面。
令人惊讶地发现，用丁酸/丁酸盐治疗的帕金森病患者使用的多巴胺量减少了至少50％，在某些情况下减少高达90％。这一点尤其重要，因为帕金森病患者的常用药物不仅仅与左旋多巴一起使用可导致相当大的副作用，例如头晕、恶心、心律加快、精神病、运动障碍和循环问题。
最后，本发明涉及单独含有丙酸和/或丁酸、其生理上可接受的盐或酯的饮食补充剂，或含有其混合物的饮食补充剂。为此，优选的是丁酸或丁酸盐，当认为合适时与丙酸或丙酸盐一起，特别是采用胶囊或片剂的形式。
胶囊或片剂形式的饮食补充剂优选含有各自盐形式的丙酸和丁酸。在这种情况下的重量比特别是3:1至1:3，总量为0.5-2.0g。
Claims (13)
1.用于帕金森病的预防性和/或支持性治疗处理的药剂，所述药剂包含生理有效量的丙酸和/或丁酸和/或其生理上可接受的盐或酯。
2.根据权利要求1所述的药剂，其特征在于所述丙酸和/或丁酸的盐是碱金属盐或碱土金属盐。
3.根据权利要求2所述的药剂，其特征在于所述盐是钠盐、钾盐、镁盐或钙盐。
4.根据前述权利要求中任一项所述的药剂，其特征在于所述酯是甲酯或乙酯。
5.根据前述权利要求中任一项所述的药剂，其为片剂、胶囊或粉剂形式。
6.根据前述权利要求中任一项所述的药剂，其特征在于所述药剂以0.2-5g的单个剂量组成。
7.根据权利要求6所述的药剂，其特征在于单个剂量含有0.5-2.0g的活性物质，并且在适当时，还含有常规制剂和辅助物质。
8.根据前述权利要求中任一项所述的药剂，其含有丙酸和丁酸或其盐或酯的组合。
9.根据权利要求8所述的药剂，其含有重量比为25/75至75/25的丙酸和丁酸或其盐或酯。
10.丙酸和丁酸或其盐和酯在制备用于帕金森病的预防和/或支持性处理的药剂中的用途。
11.饮食补充剂，含有丙酸和丁酸和/或其生理上可接受的盐或酯。
12.根据权利要求11所述的饮食补充剂，其特征在于所述补充剂含有生理相容性盐形式的丙酸和丁酸，特别是其钠盐和/或钙盐。
13.根据权利要求11或12所述的饮食补充剂，其为胶囊形式。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017115819.7A DE102017115819A1 (de) | 2017-07-13 | 2017-07-13 | Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson |
| DE102017115819.7 | 2017-07-13 | ||
| PCT/EP2018/069089 WO2019012108A1 (de) | 2017-07-13 | 2018-07-13 | Propion- und/oder buttersäure zur verwendung zur prophylaktischen und/oder unterstützenden therapeutischen behandlung von morbus parkinson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110996933A true CN110996933A (zh) | 2020-04-10 |
Family
ID=63108510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880042374.6A Pending CN110996933A (zh) | 2017-07-13 | 2018-07-13 | 用于帕金森病的预防性和/或支持性治疗处理的药剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200163914A1 (zh) |
| EP (1) | EP3651754A1 (zh) |
| JP (1) | JP7206223B2 (zh) |
| KR (1) | KR20200027976A (zh) |
| CN (1) | CN110996933A (zh) |
| AU (2) | AU2018298862A1 (zh) |
| BR (1) | BR112020000570A2 (zh) |
| CA (1) | CA3067728A1 (zh) |
| DE (1) | DE102017115819A1 (zh) |
| WO (1) | WO2019012108A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332266A (zh) * | 2021-06-10 | 2021-09-03 | 徐州医科大学 | 含丁酸的治疗与预防神经退行性疾病的药物及丁酸的应用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7234710B2 (ja) | 2019-03-14 | 2023-03-08 | ブラザー工業株式会社 | プリンタ |
| WO2021048440A1 (en) | 2019-09-13 | 2021-03-18 | Basf Se | Composition for the treatment of neurodegenerative diseases |
| CN111450238A (zh) * | 2020-03-31 | 2020-07-28 | 上海交通大学医学院附属瑞金医院 | 骨钙素或丙酸在制备抗帕金森病药物中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103415218A (zh) * | 2011-01-12 | 2013-11-27 | 阿尔贝特·达克瑟尔 | 饮料 |
| CN105055457A (zh) * | 2015-08-06 | 2015-11-18 | 温州医科大学附属第二医院 | 一种防治阿尔茨海默病的药物及其制备方法和应用 |
| JP2016530239A (ja) * | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| WO2017091072A1 (en) * | 2015-11-27 | 2017-06-01 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19503598A1 (de) * | 1995-02-03 | 1996-08-08 | Zuzana Dr Cully | Verfahren zur fermentativen Herstellung von Propionsäure oder Buttersäure bzw. deren Salze |
| NL1009990C2 (nl) * | 1998-09-02 | 2000-03-15 | Sibeco Chemicals | Voedingssupplement en werkwijze voor het vervaardigen van zulk voedingssupplement. |
| DE102016103242A1 (de) * | 2016-02-24 | 2017-08-24 | Flexopharm Brain Gmbh & Co. Kg | Mittel zur unterstützenden Immunmodulation |
| US11065217B2 (en) * | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
-
2017
- 2017-07-13 DE DE102017115819.7A patent/DE102017115819A1/de not_active Withdrawn
-
2018
- 2018-07-13 EP EP18750103.6A patent/EP3651754A1/de active Pending
- 2018-07-13 KR KR1020207003431A patent/KR20200027976A/ko not_active Application Discontinuation
- 2018-07-13 CA CA3067728A patent/CA3067728A1/en active Pending
- 2018-07-13 WO PCT/EP2018/069089 patent/WO2019012108A1/de unknown
- 2018-07-13 AU AU2018298862A patent/AU2018298862A1/en not_active Abandoned
- 2018-07-13 JP JP2019571280A patent/JP7206223B2/ja active Active
- 2018-07-13 US US16/627,688 patent/US20200163914A1/en not_active Abandoned
- 2018-07-13 CN CN201880042374.6A patent/CN110996933A/zh active Pending
- 2018-07-13 BR BR112020000570-3A patent/BR112020000570A2/pt not_active Application Discontinuation
-
2021
- 2021-11-26 AU AU2021273627A patent/AU2021273627B2/en active Active
-
2022
- 2022-06-20 US US17/807,797 patent/US20220313634A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103415218A (zh) * | 2011-01-12 | 2013-11-27 | 阿尔贝特·达克瑟尔 | 饮料 |
| JP2016530239A (ja) * | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| CN105055457A (zh) * | 2015-08-06 | 2015-11-18 | 温州医科大学附属第二医院 | 一种防治阿尔茨海默病的药物及其制备方法和应用 |
| WO2017091072A1 (en) * | 2015-11-27 | 2017-06-01 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
Non-Patent Citations (1)
| Title |
|---|
| ENIE LEI 等: "Fatty acids and their therapeutic potential in neurological disorders", 《NEUROCHEMISTRY INTERNATIONAL》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332266A (zh) * | 2021-06-10 | 2021-09-03 | 徐州医科大学 | 含丁酸的治疗与预防神经退行性疾病的药物及丁酸的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020000570A2 (pt) | 2020-07-14 |
| AU2021273627A1 (en) | 2021-12-16 |
| AU2018298862A1 (en) | 2020-01-23 |
| AU2021273627B2 (en) | 2024-01-25 |
| WO2019012108A1 (de) | 2019-01-17 |
| JP7206223B2 (ja) | 2023-01-17 |
| DE102017115819A1 (de) | 2019-01-17 |
| EP3651754A1 (de) | 2020-05-20 |
| CA3067728A1 (en) | 2019-01-17 |
| US20200163914A1 (en) | 2020-05-28 |
| KR20200027976A (ko) | 2020-03-13 |
| US20220313634A1 (en) | 2022-10-06 |
| JP2020526485A (ja) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021273627B2 (en) | Agent for the prophylactic and/or supportive therapeutic treatment of Parkinson's disease | |
| US11471432B2 (en) | Supporting immunomodulatory agent | |
| JPH07507569A (ja) | ヒトの窒素保持の促進方法 | |
| WO2016029868A1 (zh) | 用于减少体重及减少体脂肪的组合物及其医药品与应用 | |
| US11865091B2 (en) | Supporting immunomodulatory agent | |
| JP2007238441A (ja) | アスタキサンチンを有効成分とする体脂肪減少用組成物 | |
| US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
| NO20001717L (no) | Serotonin-inneholdende formulering for oral administrering og anvendelse av samme | |
| US8557236B2 (en) | Cardiovascular support supplement and compositions and methods thereof | |
| CA3078609A1 (en) | The use of a benzoate containing composition to treat glycine encephalopathy | |
| US11458150B2 (en) | Methylphosphinic acid compositions and methods for reducing aging | |
| US20130022673A1 (en) | Enhancement of magnesium uptake in mammals | |
| JP6594858B2 (ja) | メラトニン分泌調整剤、メラトニン分泌調整方法 | |
| JP2010265186A (ja) | 貧血予防用組成物 | |
| CA2166427A1 (en) | Use of bile acids for preparing medicaments for the treatment of skin diseases | |
| US20180193312A1 (en) | Nutraceutical composition and dosing regimen | |
| JPWO2009054360A1 (ja) | 内臓脂肪特異的低減剤 | |
| JPH0235057A (ja) | 機能性食品 | |
| TW201618767A (zh) | 治療不寧腿症候群及腿痙攣的組成物及方法 | |
| CN105622562B (zh) | 一种治疗心脑血管疾病的药物组合物 | |
| Buyse et al. | TO 3 SNT-MC17/idebenone in Duchenne muscular dystrophy: long-term blinded controlled preclinical study in the mdx mouse followed by a 12 month double-blind randomized controlled trial in humans | |
| CN102526088A (zh) | 维生素b12口服制剂的改进配方及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200410 |